Furthermore, pancreatic cancers have more than 90% KRAS mutation and KRAS is one of the most frequently mutated oncogenes of the RAS family, and it is reported that combinatorial therapies with TOR inhibitors will be necessary against RAS-driven cancers [62]. Here, KRAS is linked to familial pancreatic carcinoma.